alexa HMGB1 as an Innate Alarmin Promotes Autoimmune Progress: An Essential Role in the Pathogenesis of Type 1 Diabetes | Open Access Journals
ISSN: 2167-7956
Journal of Biomolecular Research & Therapeutics
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

HMGB1 as an Innate Alarmin Promotes Autoimmune Progress: An Essential Role in the Pathogenesis of Type 1 Diabetes

Jixin Zhong1,2*

1Department of Medicine, Affiliated Hospital of Guangdong Medical College, 57 Ren-Ming Road, Zhanjiang 524001, China

2Davis Heart and Lung Research Institute, The Ohio State University, 460 W 12th Ave, BRT 350, Columbus, OH 43210, USA

*Corresponding Author:
Jixin Zhong
Davis Heart and Lung Research Institute
The Ohio State University
460W 12th Ave, BRT 350, Columbus, OH 43210, USA
Tel: 1-614-556-9777
E-mail: zhongjixin620@163.com

Received date:November 23, 2012; Accepted date: November 24, 2012; Published date: November 27, 2012

Citation: Zhong J (2012) HMGB1 as an Innate Alarmin Promotes Autoimmune Progress: An Essential Role in the Pathogenesis of Type 1 Diabetes. J Biomol Res Ther 1:e108. doi: 10.4172/2167-7956.1000e108

Copyright: © 2012 Zhong J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Biomolecular Research & Therapeutics

Keywords

HMGB1; Type 1 diabetes; Autoimmune response; β cell

High-Mobility Group Box 1 Protein (HMGB1) is a chromatin associated nuclear protein which was previously thought to function only as a nuclear factor that enhances transcription [1,2]. Recent findings indicate that HMGB1 also acts as an endogenous “danger signal” (alarmin) to alert the innate immune system for the initiation of host defense or tissue repair [3]. HMGB1 was demonstrated to be either passively release or actively secreted and functioned as an inflammatory cytokine. When released from damaged cells or activated immune cells, it activates a variety of immune cells including dendritic cells (DCs), macrophages, neutrophils, and T cells. It has been suggested that HMGB1 is involved in the pathogenesis of multiple autoimmune diseases including Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Experimental Allergic Encephalomyelitis (EAE) [4,5]. We recently demonstrated that HMGB1 is also implicated in the development of type 1 diabetes via activating innate immune response [5,6].

HMGB1 belongs to a family of non-histone chromatin associated nuclear proteins, High Mobility Group (HMG) nuclear protein family. It was discovered as a specific regulator of gene expression in 1973 [7]. HMGB1 is an evolutionarily conserved chromosomal protein, sharing 100% amino acid (AA) identity between mice and rats, and 99% AA identity between rodents and humans. As a nuclear factor, HMGB1 exerts diverse cellular functions such as regulating nucleosomal structure and controlling DNA transcription [1,2,8-11]. HMGB1 has two 80-amino acid DNA binding domains (A-box and B-box) and a C-terminal acidic tail (Figure 1). The two boxes are responsible for the DNA binding and stabilization of nucleosomal structure, while the C-terminal acidic tail is important for the transcription stimulatory activity of HMGB1 [5,12-15]. Wang and coworkers re-discovered HMGB1 as a late mediator of lethal septic shock [3]. HMGB1 was found to be increased in the circulation of septic mice and patients. The administration of HMGB1 was lethal in mice. Challenge of endotoxin, Tumor Necrosis Factor (TNF), and Interleukin-1 (IL-1) induced the release of HMGB1 from macrophages. Blockade of HMGB1 by neutralizing antibodies protected mice from endotoxin-induced septic shock [3]. Further studies demonstrated that HMGB1 released from damaged tissue or cell serves as a “danger signal” to alert the innate immune system for exogenous pathogen invasion, endogenous tissue injury, or the presence of inflammatory mediators. Immune system

biomolecular-research-therapeutics-Molecular-Characterization-HMGB1

Figure 1: Molecular Characterization of HMGB1. HMGB1 contains 2 homogenous domains – A-box and B-box and an acidic C-terminal tail. B-box is associated with proinflammatory activity and RAGE binding while A-box is a specific antagonist of HMGB1 which inhibits the proinflammatory properties of HMGB1. The C-terminal acidic tail is required for transcription stimulatory function of HMGB1.

Right after re-discover as an innate alarmin, HMGB1 was suggested to be involved in a variety of autoimmune diseases such as Systemic Lupus Erythematosus (SLE) [16], Rheumatoid Arthritis (RA) [17,18], and Experimental Allergic Encephalomyelitis (EAE) [19]. Using a spontaneous type 1 diabetes animal model (Non-Obese Diabetic mouse, NOD mouse), we demonstrated an essential role of HMGB1 in the development of type 1 diabetes [5,6]. Defects in apoptotic β cell clearance have been considered as an important cause of type 1 diabetes [20-24], although the underlying mechanisms remain elusive. To illustrate the importance of HMGB1 in this process, we confirmed that HMGB1 could be passive released by apoptotic β cells, not only by necrotic cells [6]. Defective clearance of apoptotic β cells may thereby results in the accumulation of extracellular HMGB1. The release of HMGB1 subsequently induces DC maturation which can further initiate an immune response against β cell antigen in susceptible individuals. In addition to the passive release from damaged β cells, HMGB1 is also released from autoreative immune cells by active secretion. Using a neutralizing antibody, we demonstrated that blockade of HMGB1 decreased the incidence of spontaneous T1D, delayed its onset, and reduced the severity of insulitis. To further illustrate the underlying mechanism, we detected DC and T cell subpopulations and found HMGB1 neutralization reduced CD11c++ CD11b+ DCs in Pancreatic LyphoNode (PLN), a subpopulation involved in islet antigen presentation. HMGB1 blockade also increased CD4+ Foxp3+ regulatory T cells in PLN and CD11c+CD8+ DCs, a tolerogenic subset of DCs, in spleen. Interestingly, CD8+ IFNγ+ cytotoxic T cells were increased in the PLN and spleen of mice treated with HMGB1 neutralizing antibody, suggesting a retarded migration of activated autoreactive T cells into the pancreatic islets [6]. Consistent with our findings, blockade of RAGE, a receptor for HMGB1, can also delay the recurrent diabetes in syngeneic islet transplantation and prevent transfer diabetes [25].

Inflammatory response begins with recognition of life-threatening events called “danger signals”. According to their origin, those “danger signals” can be categorized into two classes: Pathogen-Associated Molecular Pattern (PAMP) and Damage-Associated Molecular Pattern (DAMP). PAMPs are exogenous molecules derived from life- threatening pathogens such as lipopolysacharide (LPS) and viral RNA, while DAMPs (also called as alarmins) are endogenous molecules released from damaged cells or tissues such as Heat Shock Proteins (HSPs). HMGB1 is now considered as a novel DAMP, alerting immune system for a tissue damage caused by either sterile inflammation or exogenous pathogen invasion. HMGB1 could be recognized by many receptors including Receptor for Advanced Glycation End products (RAGE) and some members of the Toll-like family of receptors [5,26].

Based on its importance in orchestrating immune responses, HMGB1 has been proposed to be involved in a variety of diseases. In case of autoimmune diabetes, a defective clearance of apoptotic β cells results in the release of HMGB1, which subsequently activates immune cells such as DCs and macrophages. Activated DCs and macrophages in turn actively secrete HMGB1 to amplify the immune response, intending to clear damaged β cells. In genetically susceptible individuals, however, this process may induce an autoimmune reaction against self antigens derived from β cells (Figure 2). The challenge for future studies is to develop a high potent HMGB1 blockade therapy to prevent the progress of autoimmune response against β cells and reverse Type 1 Diabetes.

biomolecular-research-therapeutics-Implication-HMGB1-autoimmune-response

Figure 2: Implication of HMGB1 in autoimmune response against β cell. Apoptotic β cells release HMGB1, which subsequently activates immune cells such as DCs and macrophages. Activated DCs and macrophages in turn secrete HMGB1 to amplify the immune response. The amplified immune reaction against apoptotic β cell then results in an autoimmune response against β-cell-derived self antigens in genetically susceptible individuals.

Acknowledgements

This work is supported by the National Natural Science Foundation of China (No. 81101553/ H1604). The author declares no competing financial interest.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11501
  • [From(publication date):
    September-2013 - Apr 30, 2017]
  • Breakdown by view type
  • HTML page views : 7758
  • PDF downloads :3743
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version